76 completed, 15 unknown, 14 terminated, 11 recruiting. 35 Phase 2, 34 Phase 3, 24 Phase 4, 21 Phase 1, 20 Not applicable.
Follow Placebo Tablets: new trials by email Literature Review of Placebo Tablets trials Research Report on Placebo Tablets
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of JMKX003142 Tablet to Treat Renal Edema JMKX003142 Tablets, Placebo Tablets - Renal Edema, Nephrogenic Edema | Phase 3 | Not yet recruiting | Jemincare | 240 | 2027-02-28 | 2026-09-30 |
| A Study to Evaluate the Efficacy and Safety of ENERGI-F705 Tablets for Parkinson's Disease 60 milligrams of ENERGI-F705 Tablets, Placebo tablets, 120 milligrams of ENERGI-F705 Tablets - Parkinson's Disease (PD) | Phase 2 | Not yet recruiting | Energenesis Biomedical Co., Ltd. | 105 | 2026-12-01 | 2026-07-02 |
| IRONCARE: Iron Treatment in Older Patients With Hip Fractures Ferric Derisomaltose, Oral Iron (Ferrous sulphate), Placebo IV - Hip Fracture, Anemia | Phase 4 | Not yet recruiting | University of Aarhus | 528 | 2026-10-01 | 2026-06-24 |
| The Impact of Dietary Salt on the Severity of Eczema Sodium chloride tablets, Placebo Tablets - Eczema, Atopic Dermatitis | Phase 4 | Recruiting | University of California, San Francisco | 40 | 2026-08-10 | 2026-09-10 |
| QT Interval/Corrected QT Interval （QT/QTc） Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy Participants TQ05105 tablets, Placebo tablets, Moxifloxacin Hydrochloride Tablets - Myelofibrosis | Phase 1 | Active not recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 60 | 2026-07-30 | 2026-08-07 |
| The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease Sodium chloride tablets, Placebo Tablets - Atopic Dermatitis (Eczema), Psoriasis | Phase 4 | Recruiting | University of California, San Francisco | 50 | 2026-07-14 | 2026-09-09 |
| A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis D-2570 Tablet, Placebo Tablets - Psoriasis | Phase 2 | Recruiting | InventisBio Co., Ltd | 75 | 2026-06-03 | 2026-07-09 |
| Doxepin Alone or Combined With Ramelteon Versus Placebo for Improving Sleep Quality After Primary Total Knee Arthroplasty Doxepin 6 mg, Ramelteon 8 mg, Placebo Tablets - Sleep Quality Post-TKA, Postoperative Knee Function | Phase 4 | Not yet recruiting | University of Washington | 129 | 2026-06-01 | 2026-05-20 |
| The Preventive and Therapeutic Effects of Spirulina Preparations on Ulcers of Oral Mucosa Spirulina Tablets, Placebo Tablets - Recurrent Aphthous Stomatitis, Mouth Ulcer | Not applicable | Recruiting | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | 40 | 2026-06-01 | 2026-07-23 |
| A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 Years ORX489 Tablets, Placebo Tablets - Healthy Adult Male and Female Volunteers | Phase 1 | Recruiting | Centessa Pharmaceuticals (UK) Limited | 212 | 2026-02-25 | 2026-02-25 |
| A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese Subjects BGM0504 tablets, Placebo tablets - Healthy, Non-diabetic Overweight or Obese | Phase 1 | Completed | BrightGene Bio-Medical Technology Co., Ltd. | 75 | 2025-10-24 | 2026-10-13 |
| A Dose-finding Study of JMKX003142 in Treatment of Renal Edema JMKX003142 tablets, Placebo Tablets - Edema Secondary, Edema Leg | Phase 2 | Completed | Jemincare | 133 | 2025-10-17 | 2026-08-10 |
| A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder Vortioxetine tablets, Placebo tablets - Major Depressive Disorder | Phase 3 | Recruiting | Takeda | 180 | 2025-10-01 | 2026-09-02 |
| A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age ORX142 Tablets, Placebo Tablets - Excessive Daytime Sleepiness | Phase 1 | Recruiting | Centessa Pharmaceuticals (UK) Limited | 208 | 2025-06-30 | 2025-12-24 |
| Eschscholzia Study Eschscholzia tablets, Placebo Tablets - Sleep | Phase 3 | Completed | A. Vogel AG | 104 | 2025-04-07 | 2026-04-06 |
| Probiotic Supplementation and Disease Progression in CKD: A Randomized Trial Probiotic Supplementation (Lactobacillus plantarum), Placebo Tablets - Kidney Disease, Chronic, Renal Insufficiency, Chronic | Phase 1 / Phase 2 | Recruiting | Mansoura University | 72 | 2025-04-03 | 2025-05-16 |
| An Extension Test of Whether to Use Oral Anti-anxiety Drugs (Alprazolam) When Patients Choose Second Eye Cataract Surgery After Unblinding, and Analyze Their Anxiety, Satisfaction and Pain Satisfaction Alprazolam (Xanax), Placebo Tablets - Ophthalmology, Cataract Surgery Anesthesia | Phase 4 | Recruiting | National Taiwan University Hospital | 250 | 2025-03-25 | 2026-04-24 |
| Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder extended-release naltrexone (XR-NTX), extended release bupropion (BUP-XL) tablets (BUP-XL), iPLB - Methamphetamine-dependence, Methamphetamine Abuse | Phase 3 | Active not recruiting | National Institute on Drug Abuse (NIDA) | 360 | 2024-07-01 | 2026-07-13 |
| A Study of Efficacy and Safety of TLL-018 in CSU Participants TLL-018 tablets, Placebo tablets - Chronic Spontaneous Urticaria | Phase 3 | Active not recruiting | Hangzhou Highlightll Pharmaceutical Co., Ltd | 440 | 2024-03-27 | 2026-06-03 |
| Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients Endoxifen enteric-coated tablet (8 mg), Placebo Tablets - Bipolar 1 Disorder | Phase 3 | Unknown | Jina Pharmaceuticals Inc. | 490 | 2024-03-19 | 2025-03-17 |
Showing 20 of 130. Sign in to see all of them.
Pain (7) · Depressive Disorder, Major (5) · Parkinson Disease (5) · Diabetes Mellitus, Type 2 (4) · Anemia (3) · Caliciviridae Infections (3) · Hematologic Diseases (3) · Inflammation (3) · Pruritus (3) · Psoriasis (3) · Amyotrophic Lateral Sclerosis (2) · Attention Deficit Disorder with Hyperactivity (2) · COVID-19 (2) · Cognitive Dysfunction (2) · Depression (2)
Vaxart (6) · Adamas Pharmaceuticals, Inc. (2) · Bial - Portela C S.A. (2) · Centessa Pharmaceuticals (UK) Limited (2) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2) · Cytokinetics (2) · Daiichi Sankyo (2) · Ferring Pharmaceuticals (2) · GlaxoSmithKline (2) · Jemincare (2) · Jiangsu HengRui Medicine Co., Ltd. (2) · Karolinska Institutet (2) · Mallinckrodt (2) · Mundipharma Research GmbH & Co KG (2) · National Taiwan University Hospital (2)
United States (47) · China (20) · Germany (17) · Canada (12) · Poland (11) · France (10) · Spain (10) · Italy (8) · United Kingdom (8) · Austria (5) · Belgium (5) · Denmark (5) · Egypt (5) · Netherlands (5) · Taiwan (5)
Angela Dentiste, MBA (2) · James Cummings, MD (2) · Katrina Abuabara, MD (2) · Raja K Sivamani, M.D. (2) · Susanna Brighenti, PhD (2) · Alberto Zanchetti, MD (1) · Amy Manley (1) · Andrea Giaccari, Prof. (1) · Andreas Zeller, Prof. Dr. med (1) · Anna Wald, MD, MPH (1) · Athol U Wells, MD FRCP FRCR (1)
PMID 10954759, PMID 16632326, PMID 17920504, PMID 18754003, PMID 19474141, PMID 19876613, PMID 20194698, PMID 20442386, PMID 20859150, PMID 20942615, PMID 21043553, PMID 21150933, PMID 21388309, PMID 21777897, PMID 21864343, PMID 21993710, PMID 22418908, PMID 22595153, PMID 22972032, PMID 23153291, PMID 23884486, PMID 24013685, PMID 24772521, PMID 24844869, PMID 24925984, PMID 24937643, PMID 25711509, PMID 26044291, PMID 26132512, PMID 26265463, PMID 26467790, PMID 27156182, PMID 27487193, PMID 27521719, PMID 27988142, PMID 28736944, PMID 29035939, PMID 29214506, PMID 29402141, PMID 29432959, PMID 29656145, PMID 29696707, PMID 29972759, PMID 30527287, PMID 30634590, PMID 31330899, PMID 31608930, PMID 31978354, PMID 32333877, PMID 32784346
2018 (2), 2008 (1), 2009 (1), 2014 (1), 2016 (1), 2017 (1), 2019 (1)